ClinicalTrials.Veeva

Menu

Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer

Fudan University logo

Fudan University

Status

Active, not recruiting

Conditions

Breast Cancer

Treatments

Drug: Trastuzumab Deruxtecan

Study type

Observational

Funder types

Other

Identifiers

NCT05594082
YOUNGBC-24

Details and patient eligibility

About

The aim of this trial is to explore the real-world effectiveness and poteintial predictors in Chinese metastatic breast cancer patients.

Enrollment

150 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients aged over 18 years old.
  2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
  3. Plan to receive or has received Trastuzumab Deruxtecan monotherapy
  4. Available medical history.

Exclusion criteria

  1. Incomplete medical history.
  2. Pregnancy or breast-breeding

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems